Tue, Sep 16, 2014, 6:29 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OCZ Technology Group Inc Message Board

rchites 499 posts  |  Last Activity: Sep 15, 2014 10:17 AM Member since: Apr 12, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • # 10 Dengue
    Global deaths per year: 25,000-The WHO estimates that a whopping 2.5 billion people (two fifths of the World’s population) are at risk from Dengue.
    # 9 Yellow fever
    Global deaths per year: 30,000
    # 8 Rabies 50,000 per year
    # 7 Hantavirus- Global deaths per year: 70,000

    # 6 Measles
    Global deaths per year: 197,000
    # 5 Hepatitis C
    Global deaths per year: 500,000 related
    # 4 Influenza
    Global deaths per year: 500,000
    # 3 Hepatitis B
    Global deaths per year: 521,000
    # 2 Rotavirus
    Global deaths per year: 611,000 - According to the WHO, this merciless virus causes the deaths of more than half a million children every year.

  • rchites rchites Aug 11, 2014 11:23 AM Flag

    I bought both as the different viruses may react differently the other drugs. TKMR was 100% effective on primates. The others have only been tested on rats. NNVC also has news out.

  • rchites rchites Aug 11, 2014 10:03 AM Flag

    read the latest press that the medical community is on stand by test have been done on MONKEYS! Daa only one company that far along. TKMR........... 100% cured............. cover you have to think of safety, availability and ready to ramp. Do some DD and find out who they are talking to for new parameters and procedures to meet the risk VS benefit standards. .

  • Reply to

    CONX CONX

    by hammer77777777 Aug 11, 2014 9:56 AM
    rchites rchites Aug 11, 2014 9:59 AM Flag

    this will be huge....... any body with a fever -thermal screen will get one. Testing will be the norm. It will take months before we get a handle if we act now.

  • Reply to

    BCRX Ebola Play Gapping Hard Now Pre-Market

    by apachebunny Aug 11, 2014 8:20 AM
    rchites rchites Aug 11, 2014 8:31 AM Flag

    is that all. THE GOVERNMENT have already called TKMR the winner with Tekmira's treatment, TKM-Ebola, is currently being developed under a $140 million contract with the Department of Defense's Medical Countermeasure Systems BioDefense Therapeutics Joint Product Management Office.

  • rchites rchites Aug 11, 2014 8:27 AM Flag

    Or who has the best backing, scalable and testing so far...... The TKMRs treatment is being developed under a $140 million contract with the U.S. Department of Defense. Analyst were on top of this drug early...... They knew it would happen , RBC Capital initiated coverage on Tekmira Pharma with an Outperform rating and a price target of $30.00. Group analyst Jason Kolbert reiterated a Buy rating and $23 price target on Tekmira Pharma (NASDAQ: TKMR) after the FDA partially lifts the hold on TKM-Ebola. The company also has hepatitis B results coming out soon that may have some bearings. The original test was for a healthy subject, Changes could include a test with people who have Ebola. THE FDA "stands ready" to work with companies developing Ebola treatments and has said they will consider different . I think TKMR is in the sweet spot and is the best option. Having a open dialog with the FDA who sought additional data as well as protocol changes to assure the safety of volunteer subjects. Risk Vs Benefit changes drastically when a person has a fatal disease..........

  • rchites rchites Aug 11, 2014 8:14 AM Flag

    actually you know very little shorty. The One used (
    .ZMAP) manufacturer can not scale and has said so in the press release. And then ZMAP was issued by a ((( third))))) party. It should also be noted that the medicine given to Brantly and Writebol was arranged by Samaritan's Purse, not the National Institutes of Health, Centers for Disease Control and Prevention, or the U.S. government. This may get around ethic and legal problems.

  • Reply to

    24.90 next stop

    by chipin8511 Aug 11, 2014 7:53 AM
    rchites rchites Aug 11, 2014 8:06 AM Flag

    30 is not out of the question today or this week. Its not only Ebola we are talking about. ONCE the drug is administered it fly's past all the other testing and results are easy to see. It should also be noted that the medicine given to Brantly and Writebol was arranged by Samaritan's Purse, not the National Institutes of Health, Centers for Disease Control and Prevention, or the U.S. government. Other virus's like ROTA,HIV, RABIES and influenza take many lives. These cousin type diseases could be another target for the experimental drugs. The viruses keep changing and the Department of defense needs a whole arsenal. The more drugs the better. One may work better then another one and the other drug on something else. THE WHO and the USA may be getting pressure for keeping the drugs (secret) or only for America. I am betting on TKMR eventual use.

  • rchites rchites Aug 8, 2014 6:01 PM Flag

    brainless blow hards sat on IPCI way to long also. from 20 dollars to 500$$$$$$$. News stations are looking for feel good stories with happy endings. Needless to say you did not do any home work of results at 100%. Backed by the WHO and DOD you are looking at hard time ahead for you. Tekmira Pharmaceuticals Corp clinical trial of TKM-Ebola, one of the few Ebola treatments advanced enough to be tested in people will do great. My money is on previous testing and science. I am very long and strong. BIOTECHs run is not over and this company will have support and a buyer.

  • rchites rchites Aug 8, 2014 3:57 PM Flag

    How about shipment in small quantities and China government places an order. CHINA is viral breading ground.

  • Reply to

    CNBC just pumped Tekmira

    by godwinpeak Aug 8, 2014 3:22 PM
    rchites rchites Aug 8, 2014 3:28 PM Flag

    They must see good in the stock as the analyst. When you look at the rest of the news GAZA ,IRAQ and destructions this should make you feel better doing some thing good with out a bomb. Heres' one for the RED /White and BLUE. With out an explosion. Bravo

  • rchites rchites Aug 8, 2014 2:25 PM Flag

    I just bought in. I own TKMR and NNVC ............I liked what I saw........ Corgenix and the VHFC were recently awarded a three-year, $2.9 million National Institutes of Health grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV® rapid diagnostic test for the Lassa fever virus. Catalyst and timing- Given the current Ebola outbreak in West Africa, the largest ever recorded, Simpson said it’s clear that point-of-care testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola and Marburg. Corgenix to exhibit AspirinWorks® Test, present abstracts, including “best abstract” for Ebola research and first-ever oral presentation… Catalyst- Study results are being presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry. Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Among its five scientific presentations, Corgenix has been awarded Best Annual Meeting Abstract for AACC 2014 in the Critical and Point of Care Testing Division for Infectious Disease poster B-068 titled “Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection.” Ebola is indigenous to Africa and is one of the deadliest viruses on the planet, with mortality rates of between 50 and 90 percent. Ebola infection is characterized by bleeding and coagulation abnormalities and can kill within 10 days to two weeks. Ebola and other viral hemorrhagic fevers are difficult to diagnose because many of the early signs and symptoms resemble those of other infectious diseases such as typhoid and malaria. Financials- “The third-quarter and nine-month results were in line with our expectations,” stated Corgenix President and Chief Executive Officer Douglass Simpson. “Year to date we are showing improved results year over year in terms of both revenues and income, indicating continued demand for our products and services. It has been a good year so far, as we improved operating profit margins in a challenging market as a result of our focus on providing value-added products for our customers, diligent expense control and margin improvement.”

  • and kick him self in the but for not owning more.

  • rchites rchites Aug 8, 2014 12:32 PM Flag

    WHY is it such a killer! because it is a virus and not bacteria, antibiotics will not help -- for example: "the flu" constantly has newer, mutated versions because it, too, is a virus. These bugs change and the big pharma boys know what has been the top stocks last year. The biotech firms and funds want the trend to continue. THEY can not miss the next Intercept Pharmaceuticals (ICPT) that went from 20 to 500 dollars in two years. This stock is granted new testing and test because of DEMAND ! Fidelity had the most ICPT in their portfolio and they are smart cookies. I bet they will buy.

  • rchites rchites Aug 8, 2014 12:16 PM Flag

    Its not just ebola..... Viruses in general as there are many to be tested

  • Reply to

    winner, winner, Ebola dinner!

    by number_6_1959 Aug 8, 2014 9:22 AM
    rchites rchites Aug 8, 2014 9:32 AM Flag

    fUNDS WILL BE PRESSED TO BUY AT THE OPEN AS SHORTS COVER. tHE TESTING WAS origionaly for healthy people. Now the FDA will work with the company for new (test changes) test with people who are sic already. The benefit to risk has been changed dramatically. 60 % mortality rate makes this a shoe in.

  • - 1 Food and Drug Administration action may enable the use of the company's TKM-Ebola drug for individuals infected with Ebola virus. The company said a Food and Drug Administration action may enable the use of the company's TKM-Ebola drug for individuals infected with Ebola virus.
    The FDA modified its full clinical hold on the company's Investigational New Drug Application for the treatment to a partial clinical hold, according to Tekmira, which said it received "verbal confirmation" from the agency.
    The world health organization has said the latest virus spread an international public health emergency that requires an extraordinary response to stop its spread. The US must finally decided to help not just its own citizens but the people of Africa as well and hopefully get control of this thing before we fight EBOLA world wide as it spreads. The The FDA, President , Congress and the House of Representatives all must act. Time is critical.
    2) This will validate the company’s technology and progress. Before Ebola, the play on this company was for it's hepatitis B results, which are due out soon enough. The sudden, unexpected piece of good fortune will make the stock double. "We are carefully evaluating options for use of the Ebola drug within accepted clinical and regulatory protocols," Tekmira Chief Executive Mark Murray said.
    The hold had been placed July 3 when the FDA sought additional data as well as protocol changes to assure the safety of volunteer subjects. The original test was for a healthy subject, Changes could include a test with people who have ebola. THE FDA "stands ready" to work with companies developing Ebola treatments.
    In its report, Reuters notes that the FDA's hold means Tekmira can't proceed with the trial placed on hold but doesn't prevent the company from initiating a new study proposal.
    And were the company to initiate a new trial in people already infected with Ebola, "the benefit-risk ratio changes completely," an FDA source told Reuters. "Anything that would shift the risk-benefit to a more favorable outcome could potentially allow the authorization of that study," the source told Reuters.
    Tekmira's treatment, TKM-Ebola, is currently being developed under a $140 million contract with the Department of Defense's Medical Countermeasure Systems BioDefense Therapeutics Joint Product Management Office.

    Read more: http://www.businessinsider.com/tekmira-pharmaceuticals-ebola-treatment-2014-8#ixzz39o4X0fXe
    TKMRs treatment, which is being developed under a $140 million contract with the U.S. Department of Defense.
    .
    3) With the Depart of Defense, WHO acting so Im guessing the DoD will use those funds. the director of the World Health Organization today said that efforts to halt the spread of the deadly virus have not been good enough. "This is an unprecedented outbreak accompanied by unprecedented challenges. The company just went to the world scene. This also puts this company technology on the map, in front of the world. 4) You couldnt pay for better advertising. Saving the world could be rewarding. And its going to reflect that in its stock price's parabolic rise over the next few months if the treatments are successful, the epidemic stopped and it is all because of TKM-Ebola.
    5) "This outbreak is moving faster than our efforts to control it. If the situation continues to deteriorate, the consequences can be catastrophic in terms of lost lives but also severe socioeconomic disruption and a high risk of spread to other countries," she warned. This outbreak has become an international event and threat. We will Pay now or later world wide. . 6) Ebola, which has a death rate of about 50 percent and has so far killed at least 932 people and infected more than 1,700 people since breaking out in Guinea earlier this year, according to the WHO. . WHO declared similar emergencies for the swine flu pandemic in 2009 and for polio in May . Dr. Margaret Chan, said the announcement is "a clear call for international solidarity" although she acknowledged that many countries would probably not have any Ebola cases. "Countries affected to date simply do not have the capacity to manage an outbreak of this size and complexity on their own," Lives are being lost because the response is too slow." 7) "inevitable", US health authorities admitted on Thursday that Ebola's spread beyond west Africa was "inevitable", and after medical charity Medecins Sans Frontieres (MSF) warned that the deadly virus was now "out of control" with more than 60 outbreak hotspots. 8) will get worste, we have failed world wide, likely to go on for month for months, Although there is no authorized drug to cure the Ebola virus, several experimental drugs are being created, including ones being developed by Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) of British Columbia. Over the past five days, the company’s stock has shot up by more than 30 percent. 9) ZMAPP- Mapp Biopharma – experimental drug was given to Nancy Writebol before she was rushed back to the USA. 10) TKMR has an option as well as BCRX. BioCryst is currently testing a drug that could be used to treat hemorrhagic fevers such as the Ebola virus and its close relative, the Marburg virus. In less then 2 years BDRX was a 10 banger. NNVC is at 4.2 and has yet to rise.

  • rchites rchites Aug 8, 2014 8:56 AM Flag

    ZMAPP by Map Bio was given to Nancy Writebol. That was untested on Humans. I am not worried about BCRX and and TKMR being rushed into human testing. Even NNVC has been running test on mice trying to regulate the dose. There will be room for many drugs as the Virus keeps mutating and changing. That's the nature of these viruses. These stocks could go ballistic. NNVC has not moved yet . BCRX is up 10 times the last couple years.

  • rchites by rchites Aug 8, 2014 8:46 AM Flag

    - 1) The world health organization has said the latest virus spread an international public health emergency that requires an extraordinary response to stop its spread. The US must finally decided to help not just its own citizens but the people of Africa as well and hopefully get control of this thing before we fight EBOLA world wide as it spreads. The President and his administration , Congress and the House of Representatives all must act. Time is critical.
    2) This will validate the company’s technology. Going across the CNBC ticker is a windfall. Before Ebola, the play on this company was for it's hepatitis B results, which are due out soon enough. The sudden, unexpected piece of good fortune will make the stock double. .
    3) With the Depart of Defense, WHO acting so Im guessing the DoD will use those funds. the director of the World Health Organization today said that efforts to halt the spread of the deadly virus have not been good enough. "This is an unprecedented outbreak accompanied by unprecedented challenges. The company just went to the world scene. This also puts this company technology on the map, in front of the world. 4) You couldnt pay for better advertising. Saving the world could be rewarding. And its going to reflect that in its stock price's parabolic rise over the next few months if the treatments are successful, the epidemic stopped and it is all because of TKM-Ebola.
    5) "This outbreak is moving faster than our efforts to control it. If the situation continues to deteriorate, the consequences can be catastrophic in terms of lost lives but also severe socioeconomic disruption and a high risk of spread to other countries," she warned. This outbreak has become an international event and threat. We will Pay now or later world wide. . 6) Ebola, which has a death rate of about 50 percent and has so far killed at least 932 people and infected more than 1,700 people since breaking out in Guinea earlier this year, according to the WHO. . WHO declared similar emergencies for the swine flu pandemic in 2009 and for polio in May . Dr. Margaret Chan, said the announcement is "a clear call for international solidarity" although she acknowledged that many countries would probably not have any Ebola cases. "Countries affected to date simply do not have the capacity to manage an outbreak of this size and complexity on their own," Lives are being lost because the response is too slow." 7) "inevitable", US health authorities admitted on Thursday that Ebola's spread beyond west Africa was "inevitable", and after medical charity Medecins Sans Frontieres (MSF) warned that the deadly virus was now "out of control" with more than 60 outbreak hotspots. 8) will get worste, we have failed world wide, likely to go on for month for months, Although there is no authorized drug to cure the Ebola virus, several experimental drugs are being created, including ones being developed by Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) of British Columbia. Over the past five days, the company’s stock has shot up by more than 30 percent. 9) ZMAPP- Mapp Biopharma – experimental drug was given to Nancy Writebol before she was rushed back to the USA. 10) TKMR has an option as well as BCRX. BioCryst is currently testing a drug that could be used to treat hemorrhagic fevers such as the Ebola virus and its close relative, the Marburg virus. In less then 2 years BDRX was a 10 banger. NNVC is at 4.2 and has yet to rise.
    BRCX has yet to test its drug on humans and its first trial was conducted on monkeys infected with the Marburg virus, not the Ebola virus.

  • Reply to

    UnAmerican biggots

    by rchites Aug 5, 2014 8:30 AM
    rchites rchites Aug 5, 2014 9:04 AM Flag

    every body on earth pays some king of tax. BUT , the GOP and corporations. The corporations are great at passing things on all right. Nothing is hidden when it comes to the corporate greed and dodging. They are the ones that think they are so smart.

OCZ
0.050.00(0.00%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.